CRSP

#1107
CRISPR Therapeutics AG - Common Shares
56.1 8 USD
-0.35%
Setor: Cuidados de saúde
Base: USD
Moeda do lucro: USD
Faixa diária
56.18
56.18
Faixa anual
35.48
78.48
Mudança diária
-0.35%
Mudança mensal
+9.47%
Mudança em 6 meses
+7.42%
Mudança anual
+52.25%
Fechamento anterior
56.3 8
Open
56.1 8
Mínimo
56.1 8
High
56.1 8
Volume
132
Abrir gráfico completo Full chart

Financials

Visão geral Relatórios Estatísticas
Trimestral Ano
  • Market Capitalization 5.42 B
  • Employee 393
  • Founded 2013
  • CEO Samarth Kulkarni
  • Website www.crisprtx.com
  • Headquarter Switzerland
  • FIGI UNKNOWN
  • Industry Biotecnologia
Receita total
Lucro líquido
Lucro básico por ação
Dívida total
Fluxo de caixa livre
Caixa e equivalentes de caixa
Índice preço/lucro
-8.11
Índice preço/fluxo de caixa
1 343.5

CRISPR Therapeutics AG - Common Shares

CRISPR Therapeutics AG is a Swiss–American biotechnology company headquartered in Zug, Switzerland. The company does business as CRISPR Therapeutics, Inc. in the United States. It was one of the first companies formed to utilize the CRISPR gene editing platform to develop medicines for the treatment of various rare and common diseases. The company has approximately 500 employees and has offices in Zug, Switzerland, Boston, Massachusetts, San Francisco, California and London, United Kingdom. Its manufacturing facility in Framingham, Massachusetts won the Facilities of the Year Award award in 2022. The company’s lead program, exagamglogene autotemcel, or exa-cel, was granted regulatory approval by the US Food and Drug Administration in December 2023.

Notícias